3. Nipah Virus Returns
Session: Symposium: Late Breaker Infectious Disease Updates
Wednesday, October 3, 2018: 2:20 PM
Room: S 305-314
Christopher Broder, PhD, Microbiology and Immunology, Uniformed Services University, Bethesda, MD

Christopher C. Broder, Ph.D. received his BS in biology and MS in molecular biology from Florida Tech in 1983 and 1985, and his PhD in microbiology and immunology from the University of Florida in 1989. From 1989-96 he was a National Research Council Research Associate and later an IRTA Fellow in the Laboratory of Viral Diseases, NIAID, NIH, in Bethesda, MD. He joined the Department of Microbiology and Immunology, Uniformed Services University (USU), Bethesda, MD as an Assistant Professor in 1996, where he is now Professor and Chair, and also Director of the Emerging Infectious Diseases Graduate Program at USU. His laboratory’s major research focus is on virus-host cell interactions with an emphasis on virus entry and receptor discovery, virus-mediated membrane fusion, vaccines and antibody therapeutics development. Current efforts focus on emerging zoonotic viruses including Nipah virus and Hendra virus and bat borne rabies-like lyssaviruses among others. Major collaborative research contributions include the model of distinct membrane fusion accessory factors as the basis for HIV-1 cell-type tropism in 1993; the discoveries of the CXCR4 and the CCR5 HIV-1 coreceptors (AAAS, Newcomb Cleveland Prize 97’); the development of the first oligomeric, HIV-1 soluble gp140 glycoprotein vaccine candidate; discovery of the host cell receptor proteins (ephrin-B2 and ephrin-B3) used by Nipah and Hendra virus for infection; development of the Hendra/Nipah soluble G glycoprotein subunit vaccine (Equivac® HeV), the first commercialized vaccine against a BSL-4 agent (Zoetis, Inc.) and now being developed as a Nipah/Hendra vaccine for human use; and development of therapeutic antiviral human monoclonal antibodies for use in people against Nipah and Hendra viruses. One mAb (m102.4) having a Phase I clinical trial in Australia completed in 2016, which has also been used by compassionate emergency protocol in 13 people in Australia and one individual in the United States. Recent honors include the 2013 Federal Laboratory Consortium Award; Australia's national science agency, CSIRO Chairman’s Medal (2013); the Cinda Helke Award for Excellence in Graduate Student Advocacy (2014) and the 2016 James J. Leonard Award for Excellence in Translational Research, and holds 17 US patents in areas related to HIV and henipaviruses. He has trained numerous fellows and graduate students and has coauthored more than 160 articles and chapters having a total citation count of >19,000.


Disclosures:

C. Broder, Zoetis, Inc.: royalty , Licensing agreement or royalty . Profectus Biosciences, Inc.: license , Licensing agreement or royalty .

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.